Literature DB >> 11278745

P-glycoprotein does not protect cells against cytolysis induced by pore-forming proteins.

R W Johnstone1, K M Tainton, A A Ruefli, C J Froelich, L Cerruti, S M Jane, M J Smyth.   

Abstract

P-glycoprotein (P-gp) is an ATP-dependent drug pump that confers multidrug resistance (MDR). In addition to its ability to efflux toxins, P-gp can also inhibit apoptosis induced by a wide array of cell death stimuli that rely on activation of intracellular caspases for full function. We therefore hypothesized that P-gp may have additional functions in addition to its role in effluxing xenotoxins that could provide protection to tumor cells against a host response. There have been a number of contradictory reports concerning the role of P-gp in regulating complement activation. Given the disparate results obtained by different laboratories and our published results demonstrating that P-gp does not affect cell death induced by another membranolytic protein, perforin, we decided to assess the role of P-gp in regulating cell lysis induced by a number of different pore-forming proteins. Testing a variety of different P-gp-expressing MDR cell lines produced following exposure of cells to chemotherapeutic agents or by retroviral gene transduction in the complete absence of any drug selection, we found no difference in sensitivity of P-gp(+ve) or P-gp(-ve) cells to the pore-forming proteins complement, perforin, or pneumolysin. Based on these results, we conclude that P-gp does not affect cell lysis induced by pore-forming proteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278745     DOI: 10.1074/jbc.M010774200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  3 in total

1.  Mechanisms of apoptosis are retained in cells with P glycoprotein-mediated drug resistance.

Authors:  A G Paleeva; G E Onishchenko; A A Shtil
Journal:  Dokl Biol Sci       Date:  2006 Mar-Apr

2.  Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.

Authors:  K E Odening; W Li; R Rutz; S Laufs; S Fruehauf; Z Fishelson; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

3.  Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models.

Authors:  Mario Sechi; Rahul K Lall; Saheed O Afolabi; Anant Singh; Dinesh C Joshi; Shing-Yan Chiu; Hasan Mukhtar; Deeba N Syed
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.